Company / R&D Expense
Anika Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$25.8M
FY2025
5-year range
$16.7M / $25.8M
FY2021-FY2025
Trend
+0.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $8M in FY2016 to $26M in FY2025.
Based on SEC 10-K filings.
$26M in FY2025 with a 5-year CAGR of +7.2%.
Improved from $22M to $26M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +3.2%
- 5-Year CAGR
- +7.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +7.2%, indicating consistent growth.
- In FY2025, r&d expense increased 0.9% year-over-year.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.8M | +0.9% |
| FY2024 | $25.5M | +17.4% |
| FY2023 | $21.8M | -7.1% |
| FY2022 | $23.4M | +40.6% |
| FY2021 | $16.7M | -8.4% |
| FY2020 | $18.2M | -3.2% |
| FY2019 | $18.8M | +75.1% |
| FY2018 | $10.7M | +19.4% |
| FY2017 | $9.0M | +10.4% |
| FY2016 | $8.1M | +15.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026